Page last updated: 2024-08-21

dronabinol and MS (Multiple Sclerosis)

dronabinol has been researched along with MS (Multiple Sclerosis) in 196 studies

Research

Studies (196)

TimeframeStudies, this research(%)All Research%
pre-19903 (1.53)18.7374
1990's4 (2.04)18.2507
2000's40 (20.41)29.6817
2010's118 (60.20)24.3611
2020's31 (15.82)2.80

Authors

AuthorsStudies
Conte, A; Vila Silván, C1
Chan, A; Silván, CV1
Borrelli, F; Cinquini, M; Dwan, K; Filippini, G; Minozzi, S1
Adjamian, P; Bagul, M; Carod-Artal, FJ; Gasperini, C; Vila Silván, C1
Chisari, CG; Fernández, Ó; Ferrer-Picón, E; Hernández Vicente, F; Patti, F; Sarroca, J; Vila Silván, C1
Dykukha, I; Essner, U; Penner, IK; Raithel, LM; Schreiber, H1
Alasvand, M; Bozorgi, H; Di Ciano, P; Ghasemi-Pirbaluti, M; Motaghi, E; Rashidi, M1
Benedetti, MD; Calabrese, M; Cardobi, N; Gajofatto, A; Gobbin, F; Turatti, M1
Berwaerts, J; Checketts, D; Chinnapongse, R; Javaid, S; Klineova, S; Lublin, F; Nicholas, J; Steinerman, JR1
Barré, T; Carrieri, P; Marcellin, F; Protopopescu, C; Radoszycki, L; Ramier, C; Roux, P; Santos, M; Testa, D1
Bunduc, S; Csupor, D; Fehérvári, P; Gergő, D; Hegyi, P; Horváth, IL; Kleiner, D; Lugosi, K1
Al-Ghezi, ZZ; Miranda, K; Nagarkatti, M; Nagarkatti, PS1
Boles Ponto, LL; Kamholz, J; Kindred, JH; Rudroff, T; Workman, CD1
Hudnall, MT; Nadler, RB; Pham, MN1
Essner, U; Henze, T; Meuth, SG; Trompke, C; Vila Silván, C1
Brescia Morra, V; Carotenuto, A; Costabile, T; De Angelis, M; De Lucia, M; Falco, F; Lanzillo, R; Moccia, M; Petruzzo, M; Russo, CV; Saccà, F1
Cortesi, PA; Cozzolino, P; Mantovani, LG; Patti, F1
Chang-Douglass, S; Mulvihill, C; Pilling, S1
Benedetti, MD; Berra, E; Bianco, A; Bruno Bossio, R; Buttari, F; Castelli, L; Cavalla, P; Cerqua, R; Chisari, CG; Costantino, G; Gasperini, C; Guareschi, A; Ippolito, D; Lanzillo, R; Maniscalco, GT; Matta, M; Paolicelli, D; Patti, F; Petrucci, L; Pontecorvo, S; Righini, I; Russo, M; Saccà, F; Salamone, G; Signoriello, E; Solaro, C; Spinicci, G; Spitaleri, D; Tavazzi, E; Trotta, M; Zaffaroni, M; Zappia, M1
Balletta, T; Bramanti, P; Calabrò, RS; Ciurleo, R; D'Aleo, G; Destro, M; La Via, C; Naro, A; Rifici, C; Russo, M; Sessa, E1
Carra, A; Fragoso, YD; Macias, MA1
Alessandria, G; Bandini, F; Capello, E; Infante, MT; Meli, R; Vestito, L1
Annunziata, P; Bergamaschi, R; Bianco, A; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Capello, E; Castelli, L; Cavalla, P; Centonze, D; Chisari, CG; Costantino, G; Cottone, S; Danni, MC; Esposito, F; Gajofatto, A; Gasperini, C; Guareschi, A; Lanzillo, R; Lus, G; Maniscalco, GT; Matta, M; Paolicelli, D; Patti, F; Petrucci, L; Pontecorvo, S; Righini, I; Rovaris, M; Sessa, E; Solaro, C; Spinicci, G; Spitaleri, D; Valentino, P; Zaffaroni, M; Zappia, M1
Jones, É; Vlachou, S1
Ab, O; Bs, R; F, S; Hb, S; K, L; Ps, S; R, T; S, G1
Bhattacharyya, S; McGoohan, KL; Velayudhan, L1
Paul, F; Silván, CV1
Bosco, A; Bratina, A; Dinoto, A; Manganotti, P; Mazzon, G; Morelli, ME; Pasquin, F; Sartori, A; Stragapede, L1
Prieto González, JM; Vila Silván, C1
De Blasiis, P; Fullin, A; Lus, G; Melone, MAB; Sampaolo, S; Sansone, M; Siani, MF; Signoriello, E1
Contreras Bolaños, LA; Guevara Moriones, N; Mejía Piñeros, AL; Moreno Vergara, AF; Rodríguez Mesa, XM; Santander González, SP1
D'haeseleer, M; D'hooghe, M; Delvaux, V; Guillaume, D; Laureys, G; Nagels, G; Popescu, V; Van Pesch, V; Vanderdonckt, P; Willekens, B1
Bergamaschi, R; Bonavita, S; Bossio, RB; Brescia Morra, V; Castelli, L; Cavalla, P; Centonze, D; Comi, G; Costantino, G; Cottone, S; Danni, MC; Francia, A; Gajofatto, A; Gasperini, C; Granata, A; Maniscalco, GT; Matta, M; Messina, S; Mirabella, M; Paolicelli, D; Patti, F; Pedà, G; Petrucci, L; Righini, I; Rovaris, M; Sessa, E; Signoriello, E; Solaro, C; Spinicci, G; Spitaleri, D; Zaffaroni, M; Zappia, M1
Aponte, R; Bruzzese, D; Chiariello, F; Florio, C; Guarcello, G; Maniscalco, GT; Manzo, V; Moreggia, O; Napolitano, M1
Bramanti, P; Giacoppo, S; Mazzon, E1
Häuser, W; Krcevski-Skvarc, N; Wells, C1
Izquierdo, G1
Linker, R1
Bramanti, A; Bramanti, P; Calabrò, RS; Ciurleo, R; Dattola, V; De Luca, R; Logiudice, AL; Naro, A; Russo, M; Sessa, E1
Buckley, N; Degenhardt, L; Farrell, M; Germanos, R; Hall, W; Nielsen, S; Pollard, J; Weier, M1
Benigni, F; Clarelli, F; Comi, G; Esposito, F; Ferrè, L; Martinelli Boneschi, F; Martinelli, V; Mascia, E; Osiceanu, AM; Sorosina, M; Unal, NT1
Castelli, L; Pozzilli, C; Prosperini, L1
Constantinescu, CS; Gershkovich, P1
Cantello, R; Danni, MC; Lus, G; Rini, A; Sarchielli, P; Signoriello, E; Tassinari, T1
Celius, EG; Vila, C1
Akmaz, B; Essner, U; Lentschat, A; Marinelli, M; Markovà, J; Trompke, C; Vila, C1
Mallada Frechín, J1
Cameron, M; Rice, J1
Arroyo González, R1
Ziemssen, T1
Marková, J1
Patti, F2
Arnold, JC; Banister, SD; Connor, M; Glass, M; McGregor, IS1
Al-Ghezi, ZZ; Alghetaa, H; Busbee, PB; Nagarkatti, M; Nagarkatti, PS1
Bianco, A; Castelli, L; Centonze, D; Cortese, A; Crisafulli, SG; De Giglio, L; Galgani, S; Grimaldi, AE; Haggiag, S; Marfia, G; Mirabella, M; Monteleone, F; Pozzilli, C; Prosperini, L1
Florek, E; Piekoszewski, W; Tkaczyk, M1
Klaschik, E; Nauck, F1
Constantinescu, CS; Tanasescu, R1
Boscá Blasco, I; Casanova-Estruch, B; Escutia Roig, M; Gil Gómez, I; Lorente Fernández, L; Monte Boquet, E; Pérez-Miralles, F; Poveda Andrés, JL1
Amato, MP; Koehler, J; Lycke, J; Oreja-Guevara, C1
Feneberg, W; Koehler, J; Meier, M; Pöllmann, W1
Pozzilli, C1
Rekand, T1
Koehler, J1
Flachenecker, P; Henze, T; Zettl, UK2
Erbe, B1
McKeage, K; Scott, LJ; Syed, YY1
Allsop, DJ; Copeland, J; Fu, S; Lewis, J; Molnar, A1
Benyamina, A; Reynaud, M1
Brunt, TM; Höner-Snoeken, K; Niesink, RJ; van de Velde, MJ; van Genugten, M1
Sedgwick, P1
Essner, U; Freidel, M; Lang, M; Prechtl, A; Schreiber, H; Tiel-Wilck, K1
Arie, S; Mahony, C1
Arroyo, R; Dechant, KL; Vila, C1
Centonze, D1
Fernández, O3
Celius, EG; Donzé, C; Izquierdo, G; Patti, F; Pöhlau, D; Trojano, M1
Garcia-Merino, A; Moreno Torres, I; Sanchez, AJ1
Colombo, C; Mosconi, P1
Batt, S1
Basinski, H; Jensen, HB; Stenager, E1
Centonze, D; Di Marzo, V1
Kramer, JL1
Bramanti, P; Calabrò, RS; D'Aleo, G; De Luca, R; Leo, A; Naro, A; Quartarone, A; Rifici, C; Russo, M; Sessa, E1
Cimas-Hernando, I; Lorenzo-González, JR; Pato-Pato, A; Rodríguez-Constenla, I1
Ruiz, L; Slof, J; Vila, C1
Lebrun, C; Vermersch, P1
Carrillo-Salinas, FJ; de Lago, E; Feliú, A; Fernández-Ruiz, J; Guaza, C; Mecha, M; Moreno-Martet, M1
Bramanti, P; Calabrò, RS; D'Aleo, G; Rifici, C; Russo, M; Sessa, E1
Dechant, KL; Meuth, SG; Vila, C1
Cocco, E; Coghe, G; Corona, F; Fenu, G; Frau, J; Lorefice, L; Mamusa, E; Marrosu, MG; Massa, R; Massole, S; Musu, L; Pau, M; Spinicci, G1
Cressey, D1
Pain, S1
Colombo, B; Comi, G; Esposito, F; Ferrè, L; Keller Sarmiento, IJ; Leocani, L; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Nuara, A; Pavan, G; Radaelli, M; Rodegher, M1
Bazinski, H; Jensen, HB; Stenager, E1
Trojano, M; Vila, C1
D'Onghia, M; Di Lecce, V; Direnzo, V; Iaffaldano, A; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S1
Trojano, M3
Vermersch, P2
Broughton, J; Gras, A1
Bramanti, P; Calabrò, RS; D'Aleo, G; Leo, A; Naro, A; Russo, M; Sessa, E1
Abbruzzese, G; Bandini, F; Canneva, S; Capello, E; Colombano, F; Currà, A; Fattapposta, F; Marinelli, L; Mori, L; Trompetto, C1
Fu, S; Molnar, A1
Barbera, N; Indorato, F; Ledda, C; Liberto, A; Romano, G1
Álvarez-Ossorio, L; Haupts, M; Jonas, A; Vila, C; Witte, K1
Amato, MP; Bergamaschi, R; Bonavita, S; Brescia Morra, V; Bruno Bossio, R; Cavalla, P; Centonze, D; Comi, G; Costantino, GF; Cottone, S; Danni, M; Francia, A; Gajofatto, A; Gasperini, C; Ghezzi, A; Iudice, A; Lus, G; Maniscalco, GT; Marrosu, MG; Matta, M; Messina, S; Mirabella, M; Montanari, E; Patti, F; Pozzilli, C; Rovaris, M; Sessa, E; Solaro, C; Spitaleri, D; Trojano, M; Valentino, P; Zappia, M1
Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P1
Bramanti, P; Calabrò, RS; De Luca, R; Naro, A; Rifici, C; Russo, M; Sessa, E; Torrisi, M1
Brunetti, A; Carotenuto, A; Cerillo, I; Cocozza, S; Inglese, M; Iodice, R; Manganelli, F; Orefice, G; Petracca, M; Saiote, C; Tedeschi, E1
Brescia Morra, V; Carotenuto, A; Florio, EB; Lanzillo, R; Massarelli, M; Pane, C; Saccà, F1
Trojano, M; Vermersch, P1
Deotto, L; Donato, F; Erro, R; Moretto, G; Squintani, G; Teatini, F; Turri, M1
Filli, L; Ghezzi, A; Landete, L; Lycke, J; Mekies, C; Solaro, C1
Flachenecker, P2
Ghezzi, A1
Keating, GM1
Lenk, R; Likar, R1
Bereza, B; Desjardins, O; Einarson, TR; Iskedjian, M; Jaszewski, B; Piwko, C1
Bari, M; Battistini, L; Bernardi, G; Buttari, F; Cencioni, MT; Centonze, D; Codecà, C; Fiore, S; Koch, G; Maccarrone, M; Mori, F; Rossi, S1
Börner, C; Höllt, V; Kraus, J; Schraven, B; Smida, M1
Alsindi, Z; Ambler, Z; Collin, C; Davies, P; Ehler, E; Notcutt, W; Nováková, I; O'Leary, C; Piková, J; Powell, K; Ratcliffe, S; Waberzinek, G; Zapletalova, O1
Collin, C; Duncombe, P; Stott, C; Wade, DT1
Kmietowicz, Z1
Bernardi, G; Buttari, F; Centonze, D; Codecà, C; Fiore, S; Koch, G; Kusayanagi, H; Monteleone, F; Mori, F1
Constantinescu, CS; De Ridder, D; Fowler, CJ; Kavia, RB; Stott, CG1
Gross, H1
Ambler, Z; Cefaro, L; Comi, G; Davies, P; Erdmann, A; Gasperini, C; Klimek, A; Mares, J; Montalban, X; Novakova, I; Novotna, A; Pozzilli, C; Ratcliffe, S; Rossi, P; Stelmasiak, Z; Vachova, M; Zapletalova, O1
Haas, J1
Di Marzo, V1
Clissold, S; Montalban, X; Sastre-Garriga, J; Vila, C1
Robson, P1
Solaro, C1
Oreja-Guevara, C2
Wade, D1
Gras, A; Slof, J1
Notcutt, WG1
Barnes, D; Hobart, JC; Mattison, PG; Slade, A; Zajicek, JP1
Collin, C; Notcutt, W; Serpell, MG1
Constantinescu, CS; Podda, G1
Altman, DG; Duncombe, P; Wright, S1
Lang, IA; Lu, L; Pearce, H; Roome, C; Shearer, J; Stein, K1
Langford, RM; Mares, J; Notcutt, W; Novakova, I; Novotna, A; Ratcliffe, S; Vachova, M1
Gramstad, L; Sagabråten, AS1
García-Merino, A1
Smith, PF3
Pertwee, RG1
Russo, EB1
Blauw, B; Hoogervorst, EL; Killestein, J; Nagelkerken, L; Polman, CH; Reif, M; Smits, M; Uitdehaag, BM1
Croxford, JL; Miller, SD1
Metz, L; Page, S1
Fox, P; Nunn, A; Sanders, H; Thompson, A; Vickery, J; Wright, D; Zajicek, J1
Baker, D; Constanti, A; Gibbons, S; Pryce, G; Whalley, BJ; Wilkinson, JD; Williamson, EM1
Capellà, D; Duran, M; Laporte, JR1
Szendrei, K1
Miller, R; Newport, S; Notcutt, W; Phillips, C; Price, M; Sansom, C; Simmons, S1
Berg, AT; Sirven, JI1
Bach, FW; Jensen, TS; Svendsen, KB2
Gattlen, B; Hagen, U; Heinzel-Gutenbrunner, M; Jobin, P; Reif, M; Schnelle, M; Tschopp, F; Vaney, C1
Berkley, KJ; Brady, CM; Dalton, C; DasGupta, R; Fowler, CJ; Wiseman, OJ1
Bateman, C; House, H; Makela, P; Robson, P; Wade, DT1
Berger, T; Bodner, T; Entner, T; Fleischhacker, WW; Kemmler, G; Kurzthaler, I; Wissel, J1
Kaminski, E; Katona, S; Sanders, H; Zajicek, J1
Sibbald, B1
Friede, T; Nurmikko, TJ; Rog, DJ; Young, CA1
Adekanmi, O; Freeman, RM; Waterfield, AE; Waterfield, MR; Wright, D; Zajicek, J1
Barnes, MP1
Collin, C; Davies, P; Mutiboko, IK; Ratcliffe, S1
Bari, M; Battistini, L; Bernardi, G; Bernardini, S; Centonze, D; De Chiara, V; Fezza, F; Furlan, R; Maccarrone, M; Martino, G; Prosperetti, C; Rossi, S1
Scully, C1
Nurmikko, TJ; Rog, DJ; Young, CA1
Burket, JA; Connor, JM; Deutsch, SI; Fox, FJ; Murphy, ME; Rosse, RB1
Clifford, DB1
Illis, LS; Martyn, CN; Thom, J1
Schwartz, RH; Voth, EA1
di Vadi, PP; Hamann, W1
Achiron, A; Biegon, A; Lavie, V; Margalit, R; Miron, S1
Gorter, RW; Hoogervorst, EL; Kalkers, NF; Killestein, J; Polman, CH; Reif, M; Staats, PG; Uitdehaag, BM; Van Loenen, AC1
Check, WA1
Lyman, WD1
Andyrsiak, T; Ellison, GW; Fairbanks, L; Myers, LW; Ungerleider, JT1

Reviews

61 review(s) available for dronabinol and MS (Multiple Sclerosis)

ArticleYear
Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
    Neuro-degenerative diseases, 2021, Volume: 21, Issue:3-4

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Observational Studies as Topic; Plant Extracts

2021
Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
    Neurodegenerative disease management, 2022, Volume: 12, Issue:3

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity

2022
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    The Cochrane database of systematic reviews, 2022, 05-05, Volume: 5

    Topics: Activities of Daily Living; Adolescent; Adult; Analgesics; Cannabinoids; Cannabis; Chronic Pain; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Neuralgia; Plant Extracts; Quality of Life; Young Adult

2022
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Expert review of neurotherapeutics, 2022, Volume: 22, Issue:6

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2022
Effects of Sativex
    Multiple sclerosis and related disorders, 2022, Volume: 68

    Topics: Cannabidiol; Cognition; Double-Blind Method; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Randomized Controlled Trials as Topic; Treatment Outcome

2022
The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:3

    Topics: Cannabidiol; Cannabis; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis

2023
Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials.
    Current neuropharmacology, 2023, Volume: 21, Issue:12

    Topics: Adult; Cannabidiol; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Randomized Controlled Trials as Topic; Treatment Outcome

2023
Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient.
    Urology, 2020, Volume: 139

    Topics: Cancer Pain; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoids; Cannabis; Chronic Pain; Cystitis, Interstitial; Dronabinol; Drug Combinations; Humans; Lower Urinary Tract Symptoms; Male; Medical Marijuana; Multiple Sclerosis; Pain, Procedural; Pelvic Pain; Urinary Incontinence

2020
Cannabis and multiple sclerosis.
    Expert review of neurotherapeutics, 2020, Volume: 20, Issue:8

    Topics: Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Drug Combinations; Humans; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Pain; Urologic Diseases

2020
A Critical Review of the Role of the Cannabinoid Compounds Δ
    Molecules (Basel, Switzerland), 2020, Oct-25, Volume: 25, Issue:21

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Baclofen; Cannabidiol; Clinical Trials as Topic; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Drug Approval; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Multiple Sclerosis; Spinal Cord; Treatment Outcome; United States; United States Food and Drug Administration

2020
Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.
    JAMA network open, 2021, 02-01, Volume: 4, Issue:2

    Topics: Aged; Anorexia; Antineoplastic Agents; Cancer Pain; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoids; Dizziness; Dose-Response Relationship, Drug; Dronabinol; Humans; Middle Aged; Multiple Sclerosis; Nausea; Neurodegenerative Diseases; Pain; Perceptual Disorders; Randomized Controlled Trials as Topic; Regression Analysis; Self Report; Vomiting

2021
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
    Expert review of neurotherapeutics, 2021, Volume: 21, Issue:5

    Topics: Analgesics, Opioid; Cannabidiol; Chronic Pain; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Registries

2021
Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases.
    Cannabis and cannabinoid research, 2021, Volume: 6, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Cannabidiol; Cannabinoids; Cannabis; Cartilage Diseases; Cytokines; Diabetes Mellitus, Type 1; Dronabinol; Humans; Immunomodulation; Lupus Erythematosus, Systemic; Mice; Multiple Sclerosis; Th17 Cells

2021
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
    Multiple sclerosis and related disorders, 2017, Volume: 17

    Topics: Cannabidiol; Clinical Trials as Topic; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Treatment Outcome

2017
Multiple sclerosis symptoms and spasticity management: new data.
    Neurodegenerative disease management, 2017, Volume: 7, Issue:6s

    Topics: Cannabidiol; Disease Management; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Oral Sprays

2017
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
    Current neurology and neuroscience reports, 2018, 02-13, Volume: 18, Issue:2

    Topics: Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Pain; Quality of Life; Randomized Controlled Trials as Topic; Systematic Reviews as Topic

2018
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
    Brain and behavior, 2018, Volume: 8, Issue:5

    Topics: Automobile Driving; Cannabidiol; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents

2018
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Current neurology and neuroscience reports, 2018, 06-19, Volume: 18, Issue:8

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Medical Marijuana; Multiple Sclerosis; Nervous System Diseases; Treatment Outcome

2018
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Expert review of neurotherapeutics, 2018, Volume: 18, Issue:10

    Topics: Baclofen; Cannabidiol; Disease Progression; Dronabinol; Drug Combinations; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Nasal Sprays; Plant Extracts; Quality of Life

2018
Dark Classics in Chemical Neuroscience: Δ
    ACS chemical neuroscience, 2019, 05-15, Volume: 10, Issue:5

    Topics: Cannabis; Chronic Pain; Dronabinol; Humans; Medical Marijuana; Multiple Sclerosis; Nausea

2019
[Marihuana and cannobinoids as medicaments].
    Przeglad lekarski, 2012, Volume: 69, Issue:10

    Topics: Arthritis, Rheumatoid; Cannabidiol; Cannabinoids; Cannabis; Contraindications; Dronabinol; Drug Combinations; Humans; Inflammatory Bowel Diseases; Multiple Sclerosis; Muscle Spasticity; Nausea; Nervous System Diseases; Pain; Plant Extracts; Vomiting

2012
[Dronabinol (delta9-tetrahydrocannabinol) in long-term treatment. Symptom control in patients with multiple sclerosis and spasticity, neuropathic pain, loss of appetite and cachexia].
    Schmerz (Berlin, Germany), 2004, Volume: 18 Suppl 2

    Topics: Analgesics, Non-Narcotic; Anorexia; Cachexia; Dose-Response Relationship, Drug; Dronabinol; Long-Term Care; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Phytotherapy; Plant Extracts; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Treatment Outcome

2004
Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:9

    Topics: Analgesics; Canada; Cannabidiol; Cannabinoids; Clinical Trials as Topic; Dronabinol; Drug Combinations; Drug Evaluation, Preclinical; Humans; Multiple Sclerosis; Neuralgia; Plant Preparations; Randomized Controlled Trials as Topic

2013
Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:12 Suppl

    Topics: Adult; Aged; Cannabidiol; Dronabinol; Drug Combinations; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Treatment Outcome

2013
THC:CBD spray and MS spasticity symptoms: data from latest studies.
    European neurology, 2014, Volume: 71 Suppl 1

    Topics: Affect; Automobile Driving; Cannabidiol; Clinical Trials as Topic; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Parasympatholytics; Plant Extracts; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic

2014
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
    Drugs, 2014, Volume: 74, Issue:5

    Topics: Adult; Cannabidiol; Cannabinoid Receptor Agonists; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Severity of Illness Index

2014
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.
    Journal of comparative effectiveness research, 2014, Volume: 3, Issue:4

    Topics: Activities of Daily Living; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Outcome Assessment, Health Care; Plant Extracts; Quality of Life

2014
Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Expert review of neurotherapeutics, 2014, Volume: 14, Issue:11

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Plant Extracts

2014
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Ugeskrift for laeger, 2014, Mar-17, Volume: 176, Issue:12A

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Treatment Outcome

2014
Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
    CNS neuroscience & therapeutics, 2015, Volume: 21, Issue:3

    Topics: Cannabidiol; Clinical Trials as Topic; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Oral Sprays; Placebo Effect

2015
Medical marijuana for cancer.
    CA: a cancer journal for clinicians, 2015, Volume: 65, Issue:2

    Topics: Analgesics, Non-Narcotic; Antiemetics; Canada; Cannabidiol; Clinical Trials as Topic; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Medical Marijuana; Multiple Sclerosis; Neoplasms; Pain; Treatment Outcome; United Kingdom; United States

2015
Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis.
    Expert review of neurotherapeutics, 2015, Volume: 15, Issue:8

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Sleep; Visual Analog Scale

2015
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Ugeskrift for laeger, 2015, May-11, Volume: 177, Issue:20

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evidence-Based Medicine; Humans; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Treatment Outcome

2015
Advances in the management of MS symptoms: real-life evidence.
    Neurodegenerative disease management, 2015, Volume: 5, Issue:6 Suppl

    Topics: Activities of Daily Living; Cannabidiol; Disease Management; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Product Surveillance, Postmarketing

2015
Advances in the management of MS symptoms: recently proposed clinical management algorithms.
    Neurodegenerative disease management, 2015, Volume: 5, Issue:6 Suppl

    Topics: Algorithms; Cannabidiol; Clinical Trials as Topic; Disease Management; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2015
THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    European neurology, 2016, Volume: 75 Suppl 1

    Topics: Accidental Falls; Cannabidiol; Depression; Dronabinol; Drug Combinations; Germany; Humans; Marijuana Abuse; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Plant Extracts; Prospective Studies; Registries; Retrospective Studies; Spain; Switzerland; Treatment Outcome; United Kingdom

2016
Techniques and technologies for the bioanalysis of Sativex®, metabolites and related compounds.
    Bioanalysis, 2016, Volume: 8, Issue:8

    Topics: Analgesics; Cannabidiol; Doping in Sports; Dronabinol; Drug Combinations; Gas Chromatography-Mass Spectrometry; Hair; Humans; Multiple Sclerosis; Plant Extracts; Workplace

2016
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:11

    Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diazepam; Dronabinol; Drug Combinations; Excitatory Amino Acid Antagonists; Gabapentin; gamma-Aminobutyric Acid; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Phenol

2016
Evolution of multiple sclerosis spasticity-associated symptoms: latest data.
    Neurodegenerative disease management, 2016, Volume: 6, Issue:6s

    Topics: Administration, Oral; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Plant Extracts; Randomized Controlled Trials as Topic

2016
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Drugs, 2017, Volume: 77, Issue:5

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2017
Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2010, Volume: 16, Issue:6

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain Measurement; Plant Extracts; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome

2010
Pathophysiology, assessment and management of multiple sclerosis spasticity: an update.
    Expert review of neurotherapeutics, 2011, Volume: 11, Issue:4 Suppl

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Reproducibility of Results; Self Report; Severity of Illness Index

2011
Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction.
    Expert review of neurotherapeutics, 2011, Volume: 11, Issue:4 Suppl

    Topics: Animals; Cannabidiol; Disease Models, Animal; Dronabinol; Drug Combinations; Endocannabinoids; Mice; Multiple Sclerosis; Muscle Spasticity; Muscle, Skeletal; Plant Extracts

2011
Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Expert review of neurotherapeutics, 2011, Volume: 11, Issue:4 Suppl

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Endocannabinoids; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality of Life; Treatment Outcome

2011
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
    Expert review of neurotherapeutics, 2011, Volume: 11, Issue:5

    Topics: Administration, Mucosal; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic

2011
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:5

    Topics: Cannabidiol; Cannabinoids; Clinical Trials as Topic; Dronabinol; Drug Combinations; Humans; Marijuana Abuse; Multiple Sclerosis; Plant Extracts; Psychotropic Drugs; Randomized Controlled Trials as Topic; Substance-Related Disorders

2011
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
    Expert review of neurotherapeutics, 2012, Volume: 12, Issue:4 Suppl

    Topics: Cannabidiol; Cannabinoids; Clinical Trials as Topic; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality of Life; Spain

2012
Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?
    Expert review of neurotherapeutics, 2012, Volume: 12, Issue:4 Suppl

    Topics: Cannabidiol; Clinical Trials as Topic; Dronabinol; Drug Combinations; Drug Tolerance; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Psychotropic Drugs

2012
Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Expert opinion on biological therapy, 2012, Volume: 12, Issue:11

    Topics: Analgesics; Animals; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Treatment Outcome; Urologic Diseases

2012
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
    Revista de neurologia, 2012, Oct-01, Volume: 55, Issue:7

    Topics: Administration, Sublingual; Cannabidiol; Clinical Trials, Phase III as Topic; Double-Blind Method; Dronabinol; Drug Combinations; Humans; Legislation, Drug; Multicenter Studies as Topic; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Powders; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Retrospective Studies; Spain; Treatment Outcome

2012
Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach.
    Trials, 2012, Oct-09, Volume: 13

    Topics: Bias; Cannabidiol; Clinical Trials, Phase III as Topic; Double-Blind Method; Dronabinol; Drug Combinations; Humans; Linear Models; Marijuana Smoking; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Plant Extracts; Randomized Controlled Trials as Topic; Research Design; Self Report; Severity of Illness Index; Treatment Outcome

2012
What place for ▾ cannabis extract in MS?
    Drug and therapeutics bulletin, 2012, Volume: 50, Issue:12

    Topics: Adult; Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Costs; Drug Interactions; Humans; Meta-Analysis as Topic; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome

2012
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:3 Suppl 1

    Topics: Anti-Dyskinesia Agents; Attitude of Health Personnel; Attitude to Health; Cannabidiol; Cannabinoid Receptor Agonists; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Costs; Drug Resistance; Germany; Health Care Costs; Humans; Multiple Sclerosis; Muscle Spasticity; Physicians; Plant Extracts; Quality of Life

2013
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:3 Suppl 1

    Topics: Anti-Dyskinesia Agents; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Clinical Trials, Phase III as Topic; Cost of Illness; Dronabinol; Drug Combinations; Drug Resistance; Drugs, Investigational; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Practice Patterns, Physicians'; Quality of Life; Randomized Controlled Trials as Topic; Spain; United Kingdom

2013
Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:6

    Topics: Analgesics, Non-Narcotic; Animals; Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Disease Models, Animal; Dronabinol; Fatty Acids, Unsaturated; Humans; Multiple Sclerosis; Muscle Weakness; Pain; Receptors, Cannabinoid; Receptors, Drug; Spasm

2002
Cannabinoids and multiple sclerosis.
    Pharmacology & therapeutics, 2002, Volume: 95, Issue:2

    Topics: Animals; Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Clinical Trials as Topic; Dronabinol; Humans; Multiple Sclerosis

2002
[News about therapeutic use of Cannabis and endocannabinoid system].
    Medicina clinica, 2004, Mar-20, Volume: 122, Issue:10

    Topics: Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Dronabinol; Endocannabinoids; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Receptors, Cannabinoid

2004
[A novel analgesics made from Cannabis].
    Ideggyogyaszati szemle, 2004, Jan-20, Volume: 57, Issue:1-2

    Topics: Analgesics; Arachidonic Acids; Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Combinations; Drugs, Investigational; Endocannabinoids; Europe; Humans; Multiple Sclerosis; Pain; Plant Extracts; Polyunsaturated Alkamides

2004
Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:5

    Topics: Analgesics; Cannabidiol; Cannabinoids; Dronabinol; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Self Administration; Sleep Wake Disorders

2006
Medicinal applications of delta-9-tetrahydrocannabinol and marijuana.
    Annals of internal medicine, 1997, May-15, Volume: 126, Issue:10

    Topics: Appetite Stimulants; Cannabis; Dronabinol; Glaucoma; Humans; Multiple Sclerosis; Muscle Spasticity; Nausea; Neoplasms

1997
Drugs of abuse and experimental autoimmune diseases.
    Advances in experimental medicine and biology, 1991, Volume: 288

    Topics: Animals; Autoimmune Diseases; Demyelinating Diseases; Disease Models, Animal; Dronabinol; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Female; Immunosuppressive Agents; Lymphocyte Activation; Male; Multiple Sclerosis; Neuritis, Autoimmune, Experimental; Polyradiculoneuropathy; Rats; Rats, Inbred Lew

1991

Trials

33 trial(s) available for dronabinol and MS (Multiple Sclerosis)

ArticleYear
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
    Multiple sclerosis and related disorders, 2023, Volume: 75

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Muscle Tonus; Randomized Controlled Trials as Topic; Spasm

2023
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    The International journal of neuroscience, 2020, Volume: 130, Issue:12

    Topics: Adult; Analgesics; Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Myalgia; Oral Sprays; Outcome Assessment, Health Care; Severity of Illness Index

2020
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.
    Multiple sclerosis and related disorders, 2021, Volume: 51

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Gait Analysis; Humans; Multiple Sclerosis; Muscle Spasticity; Walking

2021
The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.
    Medicine, 2017, Volume: 96, Issue:46

    Topics: Adolescent; Adult; Analgesics; Biomechanical Phenomena; Cannabidiol; Clinical Protocols; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neurological Rehabilitation; Oral Sprays; Robotics; Single-Blind Method; Treatment Outcome; Young Adult

2017
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Neurodegenerative disease management, 2018, Volume: 8, Issue:2

    Topics: Adult; Analgesics; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth; Multiple Sclerosis; Muscle Spasticity; Pilot Projects; Prospective Studies; Stomatitis; Taste; Taste Perception; Treatment Outcome

2018
Sativex
    The International journal of neuroscience, 2019, Volume: 129, Issue:2

    Topics: Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Prospective Studies; Treatment Outcome

2019
The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Forensic science international, 2014, Volume: 238

    Topics: Adult; Australia; Cannabidiol; Cannabinol; Chromatography, Liquid; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Multiple Sclerosis; Muscle Relaxants, Central; Oral Sprays; Pilot Projects; Plant Extracts; Saliva; Substance Abuse Detection; Tandem Mass Spectrometry

2014
Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.
    Pain medicine (Malden, Mass.), 2016, Volume: 17, Issue:6

    Topics: Adult; Brain; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Laser-Evoked Potentials; Male; Middle Aged; Multiple Sclerosis; Neuralgia; Pain Management; Pain Measurement; Plant Extracts; Transcranial Magnetic Stimulation

2016
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    European neurology, 2016, Volume: 75, Issue:5-6

    Topics: Adult; Baclofen; Cannabidiol; Clonidine; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts

2016
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex
    Acta neurologica Scandinavica, 2017, Volume: 135, Issue:4

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Motor Neurons; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Pyramidal Tracts

2017
Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2009, Volume: 30, Issue:6

    Topics: Adult; Arachidonic Acids; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Endocannabinoids; Female; Humans; Lymphocytes; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain; Plant Extracts; Polyunsaturated Alkamides; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Reflex, Stretch; Treatment Outcome; Young Adult

2009
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
    Neurological research, 2010, Volume: 32, Issue:5

    Topics: Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Plant Extracts; Severity of Illness Index; Time Factors; Treatment Outcome

2010
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2010, Volume: 16, Issue:11

    Topics: Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Plant Extracts; Urinary Bladder, Overactive

2010
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
    European journal of neurology, 2011, Volume: 18, Issue:9

    Topics: Adult; Aged; Cannabidiol; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2011
Multiple sclerosis and extract of cannabis: results of the MUSEC trial.
    Journal of neurology, neurosurgery, and psychiatry, 2012, Volume: 83, Issue:11

    Topics: Adolescent; Adult; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Muscle Tonus; Pain; Phytotherapy; Plant Extracts; Self Report; Severity of Illness Index; Sleep; Walking

2012
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
    Journal of neurology, 2013, Volume: 260, Issue:1

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Electrocardiography; Female; Humans; Longitudinal Studies; Male; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Pain Measurement; Phytotherapy; Plant Extracts; Sleep

2013
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Journal of neurology, 2013, Volume: 260, Issue:4

    Topics: Administration, Mucosal; Administration, Oral; Adult; Analgesics, Non-Narcotic; Analysis of Variance; Cannabidiol; Double-Blind Method; Dronabinol; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Neuralgia; Pain Measurement; Treatment Outcome

2013
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
    Lancet (London, England), 2003, Nov-08, Volume: 362, Issue:9395

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Female; Humans; Locomotion; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Outcome Assessment, Health Care; Physical Examination; Placebos; Secondary Prevention; Treatment Outcome; United Kingdom; Walking

2003
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.
    Anaesthesia, 2004, Volume: 59, Issue:5

    Topics: Administration, Sublingual; Adult; Aged; Analgesics, Non-Narcotic; Cannabidiol; Chronic Disease; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Pain Measurement; Patient Selection; Sleep; Treatment Outcome

2004
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
    BMJ (Clinical research ed.), 2004, Jul-31, Volume: 329, Issue:7460

    Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Cannabinoids; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Treatment Outcome

2004
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:4

    Topics: Administration, Oral; Cannabidiol; Capsules; Cross-Over Studies; Double-Blind Method; Dronabinol; Humans; Movement; Multiple Sclerosis; Muscle Spasticity; Sleep

2004
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:4

    Topics: Aerosols; Cannabidiol; Cannabis; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Humans; Mouth Mucosa; Multiple Sclerosis; Muscle Spasticity; Pain; Pain Measurement; Plant Extracts; Tremor; Urinary Bladder Diseases

2004
The effect of nabilone on neuropsychological functions related to driving ability: an extended case series.
    Human psychopharmacology, 2005, Volume: 20, Issue:4

    Topics: Adult; Aged; Antiemetics; Attention; Automobile Driving; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Memory, Short-Term; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain; Prospective Studies; Psychomotor Performance; Reaction Time

2005
Cannabinoid influence on cytokine profile in multiple sclerosis.
    Clinical and experimental immunology, 2005, Volume: 140, Issue:3

    Topics: C-Reactive Protein; Cannabinoids; Cannabis; Cells, Cultured; Cytokines; Double-Blind Method; Dronabinol; Female; Humans; Immunologic Factors; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Multiple Sclerosis; Phytotherapy; Plant Oils

2005
[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication].
    Ugeskrift for laeger, 2005, Jun-20, Volume: 167, Issue:25-31

    Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pain; Pain Measurement; Treatment Outcome

2005
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
    Neurology, 2005, Sep-27, Volume: 65, Issue:6

    Topics: Administration, Oral; Adult; Aged; Analgesics; Cannabinoids; Central Nervous System; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Dronabinol; Female; Humans; Male; Memory Disorders; Middle Aged; Multiple Sclerosis; Pain Measurement; Pain Threshold; Pain, Intractable; Phytotherapy; Placebos; Plant Preparations; Sleep Wake Disorders; Treatment Outcome

2005
The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS).
    International urogynecology journal and pelvic floor dysfunction, 2006, Volume: 17, Issue:6

    Topics: Analgesics, Non-Narcotic; Cannabidiol; Cannabinoids; Comorbidity; Dronabinol; Female; Humans; Middle Aged; Multiple Sclerosis; Quality of Life; Urinary Incontinence, Urge; Urination; Urodynamics

2006
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    European journal of neurology, 2007, Volume: 14, Issue:3

    Topics: Administration, Oral; Adult; Cannabidiol; Cannabinoids; Central Nervous System; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Placebos; Plant Extracts; Treatment Outcome

2007
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Clinical therapeutics, 2007, Volume: 29, Issue:9

    Topics: Administration, Oral; Administration, Sublingual; Adult; Aerosols; Analgesics, Opioid; Cannabidiol; Central Nervous System Diseases; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Pain; Plant Extracts

2007
Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
    CNS spectrums, 2008, Volume: 13, Issue:5

    Topics: Adult; Cannabis; Dronabinol; Female; Hallucinogens; Humans; Male; Marijuana Abuse; Multiple Sclerosis; Nocturnal Paroxysmal Dystonia; Phytotherapy; Tics

2008
Tetrahydrocannabinol for tremor in multiple sclerosis.
    Annals of neurology, 1983, Volume: 13, Issue:6

    Topics: Adult; Ataxia; Clinical Trials as Topic; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Placebos; Tremor

1983
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Neurology, 2002, May-14, Volume: 58, Issue:9

    Topics: Administration, Oral; Cannabinoids; Cannabis; Cross-Over Studies; Double-Blind Method; Dronabinol; Health Status; Humans; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Muscle Tonus; Pain Measurement; Plant Extracts; Sample Size; Treatment Outcome

2002
Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
    Advances in alcohol & substance abuse, 1987, Volume: 7, Issue:1

    Topics: Administration, Oral; Adult; Clinical Trials as Topic; Disability Evaluation; Dronabinol; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Random Allocation

1987

Other Studies

102 other study(ies) available for dronabinol and MS (Multiple Sclerosis)

ArticleYear
A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
    European journal of neurology, 2022, Volume: 29, Issue:9

    Topics: Cannabidiol; Central Nervous System Diseases; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Cramp; Muscle Spasticity; Pain; Spasm; Treatment Outcome

2022
Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity.
    BMC neurology, 2023, Mar-29, Volume: 23, Issue:1

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Humans; Male; Multiple Sclerosis; Muscle Spasticity

2023
Cannabis-based products and multiple sclerosis-related pain: The role of routes of administration.
    Multiple sclerosis and related disorders, 2023, Volume: 77

    Topics: Cannabis; Dronabinol; Humans; Multiple Sclerosis; Pain

2023
Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Animals; Anti-Inflammatory Agents; Brain; Cannabidiol; Cells, Cultured; Cytokines; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Leukocytes, Mononuclear; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Multiple Sclerosis; Signal Transduction; Spinal Cord; Spleen

2019
The effects of chronic Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) use on cerebral glucose metabolism in multiple sclerosis: a pilot study.
    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 2020, Volume: 45, Issue:4

    Topics: Adult; Aged; Cannabidiol; Cerebral Cortex; Dronabinol; Female; Glucose; Humans; Male; Middle Aged; Multiple Sclerosis; Pilot Projects

2020
Predictors of Nabiximols (Sativex
    Journal of neurology, 2020, Volume: 267, Issue:6

    Topics: Adult; Analgesics, Non-Narcotic; Cannabidiol; Cognitive Dysfunction; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Patient Compliance; Patient Dropouts; Retrospective Studies; Severity of Illness Index

2020
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis.
    Clinical drug investigation, 2020, Volume: 40, Issue:4

    Topics: Adult; Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Quality of Life; Quality-Adjusted Life Years

2020
Cannabis-based medicinal products: summary of NICE guidance.
    BMJ (Clinical research ed.), 2020, Apr-21, Volume: 369

    Topics: Antiemetics; Antineoplastic Agents; Cannabidiol; Cannabinoid Receptor Agonists; Chronic Pain; Decision Making, Shared; Dronabinol; Drug and Narcotic Control; Drug Resistant Epilepsy; Epilepsies, Myoclonic; Humans; Lennox Gastaut Syndrome; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Nausea; Needs Assessment; Physicians, Primary Care; Practice Guidelines as Topic; Specialization; United Kingdom; Vomiting

2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020, Volume: 41, Issue:10

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Italy; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Retrospective Studies

2020
Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.
    Multiple sclerosis and related disorders, 2020, Volume: 43

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Gait; Humans; Multiple Sclerosis; Robotic Surgical Procedures

2020
Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study.
    Clinical neurology and neurosurgery, 2020, Volume: 196

    Topics: Adult; Aged; Cannabidiol; Cognition; Cognition Disorders; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuropsychological Tests; Oral Sprays; Parasympatholytics; Pilot Projects; Prospective Studies; Single-Blind Method; Young Adult

2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
    Journal of neurology, neurosurgery, and psychiatry, 2020, Volume: 91, Issue:9

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Patient Compliance; Prospective Studies; Time Factors; Treatment Outcome; Withholding Treatment

2020
Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis.
    Multiple sclerosis and related disorders, 2021, Volume: 48

    Topics: Cannabidiol; Cannabis; Dronabinol; Humans; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Oils

2021
Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
    Neurodegenerative disease management, 2021, Volume: 11, Issue:2

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Goals; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pilot Projects; Plant Extracts; Proof of Concept Study; Prospective Studies; Quality of Life; Treatment Outcome

2021
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021, Volume: 42, Issue:12

    Topics: Botulinum Toxins; Botulinum Toxins, Type A; Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Retrospective Studies; Spasm; Treatment Outcome

2021
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    BMC neurology, 2021, Jun-22, Volume: 21, Issue:1

    Topics: Belgium; Cannabidiol; Cannabinoids; Dronabinol; Drug Administration Schedule; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Patient Reported Outcome Measures; Plant Extracts; Quality of Life; Retrospective Studies; Severity of Illness Index

2021
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Cannabidiol; Cost Sharing; Dronabinol; Drug Approval; Drug Combinations; Drug Costs; Drug Industry; Female; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Multivariate Analysis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Proportional Hazards Models; Registries; Regression Analysis; Severity of Illness Index; Young Adult

2017
THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018, Volume: 39, Issue:1

    Topics: Administration, Mucosal; Administration, Oral; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Pilot Projects; Prospective Studies; Treatment Outcome; Urinary Bladder, Overactive

2018
Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
    European journal of pain (London, England), 2018, Volume: 22, Issue:3

    Topics: Antiemetics; Antineoplastic Agents; Cannabidiol; Cannabinoid Receptor Agonists; Chronic Pain; Dronabinol; Drug Approval; Drug Combinations; Europe; Germany; Humans; Israel; Medical Marijuana; Multiple Sclerosis; Muscle Spasticity; Nausea; Pain Management; Palliative Care; Societies, Medical; Surveys and Questionnaires; Vomiting

2018
What's new in multiple sclerosis spasticity research? Poster session highlights.
    Neurodegenerative disease management, 2017, Volume: 7, Issue:6s

    Topics: Cannabidiol; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Oral Sprays

2017
Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.
    European journal of neurology, 2018, Volume: 25, Issue:7

    Topics: Adult; Cannabidiol; Down-Regulation; Dronabinol; Drug Combinations; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Sclerosis

2018
Balance worsening associated with nabiximols in multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2019, Volume: 25, Issue:1

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Postural Balance; Psychomotor Performance; Stroop Test

2019
Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited.
    European journal of neurology, 2018, Volume: 25, Issue:7

    Topics: Cannabidiol; Cannabinoids; Down-Regulation; Dronabinol; Drug Combinations; Humans; Immunomodulation; Multiple Sclerosis

2018
Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Neurodegenerative disease management, 2018, Volume: 8, Issue:3

    Topics: Activities of Daily Living; Adult; Cannabidiol; Dronabinol; Drug Combinations; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome

2018
Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
    Neurodegenerative disease management, 2019, Volume: 9, Issue:2s

    Topics: Administration, Mucosal; Cannabidiol; Cannabinoid Receptor Modulators; Congresses as Topic; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Randomized Controlled Trials as Topic; Societies, Medical

2019
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
    Neurodegenerative disease management, 2019, Volume: 9, Issue:2s

    Topics: Administration, Mucosal; Affect; Cannabidiol; Cannabinoid Receptor Modulators; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Outcome and Process Assessment, Health Care; Randomized Controlled Trials as Topic

2019
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
    Neurodegenerative disease management, 2019, Volume: 9, Issue:2s

    Topics: Administration, Mucosal; Cannabidiol; Cannabinoid Receptor Modulators; Dronabinol; Drug Approval; Drug Combinations; Humans; Italy; Multiple Sclerosis; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Pragmatic Clinical Trials as Topic; Registries

2019
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
    Brain, behavior, and immunity, 2019, Volume: 82

    Topics: Animals; Cannabidiol; Cannabinoids; Cannabis; Cytokines; Disease Models, Animal; Dronabinol; Dysbiosis; Encephalomyelitis, Autoimmune, Experimental; Female; Gastrointestinal Microbiome; Inflammation; Interferon-gamma; Interleukin-17; Mice; Mice, Inbred C57BL; Multiple Sclerosis; RNA, Ribosomal, 16S

2019
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    PloS one, 2019, Volume: 14, Issue:7

    Topics: Cannabidiol; Combined Modality Therapy; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Physical Therapy Modalities; Withholding Treatment

2019
Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Neurologia (Barcelona, Spain), 2014, Volume: 29, Issue:5

    Topics: Adult; Aged; Analgesics, Non-Narcotic; Cannabidiol; Dronabinol; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pain; Retrospective Studies; Treatment Outcome

2014
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    The International journal of neuroscience, 2014, Volume: 124, Issue:9

    Topics: Adult; Cannabidiol; Disability Evaluation; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Retrospective Studies; Treatment Outcome

2014
Overview of MS spasticity.
    European neurology, 2014, Volume: 71 Suppl 1

    Topics: Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts; Practice Guidelines as Topic

2014
Who benefits most from THC:CBD spray? Learning from clinical experience.
    European neurology, 2014, Volume: 71 Suppl 1

    Topics: Activities of Daily Living; Adult; Aged; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Parasympatholytics; Plant Extracts; Quality of Life; Severity of Illness Index; Spinal Cord; Treatment Outcome

2014
Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
    European neurology, 2014, Volume: 71, Issue:5-6

    Topics: Adult; Aged; Cannabidiol; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuromuscular Agents; Plant Extracts; Prospective Studies; Severity of Illness Index; Sleep; Surveys and Questionnaires; Treatment Outcome; Young Adult

2014
[Cannabis - medicinal use].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:3

    Topics: Administration, Oral; Affect; Cannabidiol; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Germany; Humans; Marijuana Abuse; Marijuana Smoking; Medical Marijuana; Multiple Sclerosis; Pain, Intractable; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Receptors, Cannabinoid; Risk Factors; Wasting Syndrome

2014
[Therapeutic use of cannabis derivatives].
    La Revue du praticien, 2014, Volume: 64, Issue:2

    Topics: Antiemetics; Cannabidiol; Dronabinol; Drug Combinations; Fibromyalgia; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Plant Extracts

2014
Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Cannabidiol; Cannabis; Chronic Pain; Cross-Sectional Studies; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Netherlands; Patient Satisfaction; Phytotherapy; Plant Preparations; Psychometrics; Surveys and Questionnaires; Treatment Outcome; Young Adult

2014
Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    European neurology, 2014, Volume: 72, Issue:1-2

    Topics: Adult; Aged; Analgesics; Cannabidiol; Dronabinol; Drug Combinations; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Patient Satisfaction; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome

2014
Delta-9-tetrahydrocannabinol + cannabidiol. A reasonable option for some patients with multiple sclerosis.
    Prescrire international, 2014, Volume: 23, Issue:150

    Topics: Administration, Mucosal; Aerosols; Cannabidiol; Dronabinol; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Packaging; Drug Storage; Evidence-Based Medicine; Humans; Multiple Sclerosis; Neuromuscular Agents; Treatment Outcome

2014
What is a crossover trial?
    BMJ (Clinical research ed.), 2014, May-09, Volume: 348

    Topics: Cannabinoid Receptor Agonists; Cross-Over Studies; Dronabinol; Humans; Multiple Sclerosis; Neuralgia; Randomized Controlled Trials as Topic; Research Design

2014
Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
    Acta neurologica Scandinavica, 2015, Volume: 131, Issue:1

    Topics: Adult; Automobile Driving; Cannabidiol; Dronabinol; Drug Combinations; Female; Germany; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Pilot Projects; Plant Extracts

2015
Should patient groups be more transparent about their funding?
    BMJ (Clinical research ed.), 2014, Sep-29, Volume: 349

    Topics: Analgesics; Cannabidiol; Capital Financing; Charities; Dronabinol; Drug Combinations; Drug Industry; Humans; Multiple Sclerosis; Self-Help Groups; United Kingdom

2014
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity nervous pathways.
    European neurology, 2014, Volume: 72 Suppl 1

    Topics: Animals; Cannabidiol; Dronabinol; Drug Combinations; Endocannabinoids; Humans; Motor Cortex; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Muscle, Skeletal; Neural Pathways; Plant Extracts; Spinal Cord

2014
Advances in the management of multiple sclerosis spasticity: recent clinical trials.
    European neurology, 2014, Volume: 72 Suppl 1

    Topics: Affect; Cannabidiol; Clinical Trials, Phase III as Topic; Cognition; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Plant Extracts; Randomized Controlled Trials as Topic

2014
Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
    European neurology, 2014, Volume: 72 Suppl 1

    Topics: Activities of Daily Living; Cannabidiol; Cost of Illness; Dronabinol; Drug Combinations; Europe; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Plant Extracts; Quality of Life

2014
Advances in the management of MS spasticity: recent observational studies.
    European neurology, 2014, Volume: 72 Suppl 1

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Germany; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Plant Extracts; Registries; Spain; United Kingdom

2014
Transparency of funding of patient groups is mandatory but is not enough.
    BMJ (Clinical research ed.), 2014, Oct-21, Volume: 349

    Topics: Analgesics; Cannabidiol; Capital Financing; Charities; Dronabinol; Drug Industry; Humans; Multiple Sclerosis

2014
Who will support independent patient groups?
    BMJ (Clinical research ed.), 2014, Oct-21, Volume: 349

    Topics: Analgesics; Cannabidiol; Capital Financing; Charities; Dronabinol; Drug Industry; Humans; Multiple Sclerosis

2014
Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
    Neural plasticity, 2015, Volume: 2015

    Topics: Cannabidiol; Cannabinoid Receptor Agonists; Cerebral Cortex; Dronabinol; Drug Combinations; Evoked Potentials, Motor; Humans; Multiple Sclerosis; Muscle Spasticity; Neural Inhibition; Plant Extracts; Pyramidal Tracts; Sensorimotor Cortex; Transcranial Magnetic Stimulation

2015
[Assessment of the effectiveness and safety of Sativex® in compassionate use].
    Revista de neurologia, 2015, Mar-01, Volume: 60, Issue:5

    Topics: Adult; Aged; Cannabidiol; Compassionate Use Trials; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Treatment Outcome

2015
Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
    Expert review of pharmacoeconomics & outcomes research, 2015, Volume: 15, Issue:3

    Topics: Cannabidiol; Cost of Illness; Cost-Benefit Analysis; Delivery of Health Care; Dronabinol; Drug Combinations; Humans; Italy; Markov Chains; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality-Adjusted Life Years

2015
[A breakthrough for the treatment of spasticity in multiple sclerosis].
    Revue neurologique, 2015, Volume: 171, Issue:4

    Topics: Cannabidiol; Cannabis; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts

2015
A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
    British journal of pharmacology, 2015, Volume: 172, Issue:14

    Topics: Animals; Cannabidiol; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Mice; Mice, Inbred Strains; Multiple Sclerosis; Plant Extracts; Theilovirus

2015
Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2015, Apr-17, Volume: 23

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Middle Aged; Multiple Sclerosis; Self-Injurious Behavior; Suicidal Ideation

2015
Walking improvements with nabiximols in patients with multiple sclerosis.
    Journal of neurology, 2015, Volume: 262, Issue:11

    Topics: Adult; Biomechanical Phenomena; Cannabidiol; Dronabinol; Drug Combinations; Female; Gait Disorders, Neurologic; Humans; Male; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care; Severity of Illness Index; Walking

2015
The cannabis experiment.
    Nature, 2015, Aug-20, Volume: 524, Issue:7565

    Topics: Adolescent; Appetite; Biomedical Research; Cannabis; Child; Colorado; Confounding Factors, Epidemiologic; Dronabinol; Humans; Marijuana Abuse; Marijuana Smoking; Medical Marijuana; Multiple Sclerosis; Netherlands; New Zealand; Prevalence; Schizophrenia; Seizures; Sweden; Young Adult

2015
A potted history.
    Nature, 2015, Sep-24, Volume: 525, Issue:7570

    Topics: Animals; Canada; Cannabidiol; Cannabinol; Cannabis; China; Dronabinol; Drug and Narcotic Control; Drug Approval; Drug Combinations; Endocannabinoids; Herbal Medicine; History, 16th Century; History, 17th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; History, Medieval; Humans; Medical Marijuana; Multiple Sclerosis; New Orleans; Phytotherapy; Plant Extracts; Plants, Medicinal; Receptors, Cannabinoid

2015
Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:2

    Topics: Adult; Cannabidiol; Cohort Studies; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Severity of Illness Index; Treatment Outcome

2016
Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    European neurology, 2015, Volume: 74, Issue:3-4

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Prospective Studies

2015
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:7

    Topics: Adult; Aged; Cannabidiol; Cohort Studies; Dronabinol; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Time Factors; Treatment Outcome; Young Adult

2016
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Expert review of pharmacoeconomics & outcomes research, 2016, Volume: 16, Issue:6

    Topics: Adult; Cannabidiol; Cost Savings; Cost-Benefit Analysis; Dronabinol; Hospitalization; Humans; Markov Chains; Models, Economic; Multiple Sclerosis; Muscle Spasticity; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Wales

2016
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
    European neurology, 2016, Volume: 75 Suppl 1

    Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxylic Acids; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Germany; Humans; Italy; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Observational Studies as Topic; Oral Sprays; Plant Extracts; Pregabalin; Prospective Studies; Treatment Outcome

2016
Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    European neurology, 2016, Volume: 75 Suppl 1

    Topics: Adult; Cannabidiol; Data Collection; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Plant Extracts; Prospective Studies; Registries; Treatment Outcome

2016
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    International clinical psychopharmacology, 2016, Volume: 31, Issue:4

    Topics: Administration, Oral; Adult; Aged; Analgesics; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Muscle Spasticity; Reflex, Stretch; Treatment Outcome

2016
The therapeutic use of cannabinoids: Forensic aspects.
    Forensic science international, 2016, Volume: 265

    Topics: Administration, Inhalation; Analgesics, Non-Narcotic; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Female; Forensic Toxicology; Humans; Male; Middle Aged; Multiple Sclerosis; Pain, Intractable

2016
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
    Journal of neurology, neurosurgery, and psychiatry, 2016, Volume: 87, Issue:9

    Topics: Administration, Oral; Cannabidiol; Dronabinol; Drug Combinations; Humans; Italy; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Safety

2016
Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:14

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Follow-Up Studies; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2016
The use of medical-grade cannabis in patients non-responders to Nabiximols.
    Journal of the neurological sciences, 2016, Sep-15, Volume: 368

    Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Medical Marijuana; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Retrospective Studies; Treatment Outcome

2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    European neurology, 2016, Volume: 76, Issue:5-6

    Topics: Activities of Daily Living; Adult; Baclofen; Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Oral Sprays; Plant Extracts; Prospective Studies; Quality of Life

2016
Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Journal of the neurological sciences, 2016, Nov-15, Volume: 370

    Topics: Adult; Aged; Cannabidiol; Cannabinoid Receptor Modulators; Disability Evaluation; Dronabinol; Drug Combinations; Evoked Potentials, Motor; Female; Follow-Up Studies; H-Reflex; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Nasal Sprays; Neuromuscular Agents; Oral Sprays; Plant Extracts; Severity of Illness Index; Treatment Outcome

2016
Country breakout session highlights.
    Neurodegenerative disease management, 2016, Volume: 6, Issue:6s

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Europe; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Muscle Spasticity

2016
What is new in multiple sclerosis spasticity research? Poster session highlights.
    Neurodegenerative disease management, 2016, Volume: 6, Issue:6s

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity

2016
[Cannabinoids in medicine].
    Wiener medizinische Wochenschrift (1946), 2008, Volume: 158, Issue:23-24

    Topics: Adenocarcinoma; Analgesics; Analgesics, Opioid; Dronabinol; Drug Therapy, Combination; Female; Humans; Middle Aged; Multiple Sclerosis; Pain, Intractable; Palliative Care; Quality of Life; Uterine Neoplasms

2008
Willingness to pay for a treatment for pain in multiple sclerosis.
    PharmacoEconomics, 2009, Volume: 27, Issue:2

    Topics: Administration, Oral; Administration, Sublingual; Adult; Aerosols; Aged; Aged, 80 and over; Analgesics, Opioid; Attitude to Health; Cannabidiol; Cost-Benefit Analysis; Decision Making; Dronabinol; Drug Combinations; Fees and Charges; Female; Humans; Insurance, Health; Interviews as Topic; Male; Middle Aged; Multiple Sclerosis; Pain; Patient Satisfaction; Plant Extracts; Surveys and Questionnaires

2009
Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling.
    The Journal of biological chemistry, 2009, Dec-18, Volume: 284, Issue:51

    Topics: Arachidonic Acids; Cannabinoids; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dronabinol; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Indoles; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Morpholines; Multiple Sclerosis; Phosphorylation; Protein-Tyrosine Kinases; Psychotropic Drugs; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Antigen, T-Cell; Signal Transduction; src-Family Kinases; T-Lymphocytes

2009
Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
    Prescrire international, 2009, Volume: 18, Issue:103

    Topics: Administration, Oral; Administration, Sublingual; Cannabinoids; Cannabis; Dronabinol; Humans; Marijuana Smoking; Meta-Analysis as Topic; Multiple Sclerosis; Neuralgia; Pain; Phytotherapy; Plant Preparations; Randomized Controlled Trials as Topic

2009
Cannabis based drug is licensed for spasticity in patients with MS.
    BMJ (Clinical research ed.), 2010, Jun-22, Volume: 340

    Topics: Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Approval; Drug Combinations; Humans; Multiple Sclerosis; Muscle Spasticity; Parasympatholytics; Plant Extracts

2010
Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans.
    Brain stimulation, 2009, Volume: 2, Issue:4

    Topics: Adult; Animals; Cannabidiol; Cannabinoids; Dronabinol; Drug Combinations; Evoked Potentials, Motor; Female; Humans; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Middle Aged; Motor Cortex; Multiple Sclerosis; Neuronal Plasticity; Plant Extracts; Theta Rhythm; Transcranial Magnetic Stimulation

2009
[Cannabis medicinal drugs. "Psychedelics" by prescription?].
    MMW Fortschritte der Medizin, 2010, Nov-11, Volume: 152, Issue:45

    Topics: Cannabidiol; Cannabis; Dronabinol; Drug Approval; Drug Combinations; Germany; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Palliative Care; Phytotherapy; Plant Extracts; Psychoses, Substance-Induced

2010
Evaluate symptomatic therapy in MS: can clinical trials be fine-tuned?
    European journal of neurology, 2011, Volume: 18, Issue:9

    Topics: Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Male; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2011
Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
    Expert review of pharmacoeconomics & outcomes research, 2012, Volume: 12, Issue:4

    Topics: Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Costs; Drug Resistance; Germany; Humans; Markov Chains; Multiple Sclerosis; Muscle Spasticity; Plant Extracts; Quality-Adjusted Life Years; Severity of Illness Index; Spain

2012
A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
    Primary health care research & development, 2013, Volume: 14, Issue:2

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cannabidiol; Caregivers; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Off-Label Use; Phytotherapy; Plant Extracts; Practice Patterns, Physicians'; Sleep; Surveys and Questionnaires; United Kingdom

2013
Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
    PharmacoEconomics, 2012, Dec-01, Volume: 30, Issue:12

    Topics: Administration, Mucosal; Administration, Oral; Cannabidiol; Cost-Benefit Analysis; Dronabinol; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Markov Chains; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Plant Extracts; Quality-Adjusted Life Years; Severity of Illness Index; United Kingdom

2012
[Cannabis medicines in Norway--the basis for approval].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Dec-11, Volume: 132, Issue:23-24

    Topics: Cannabidiol; Dronabinol; Drug Approval; Drug Combinations; Drug Therapy, Combination; Humans; Multiple Sclerosis; Muscle Spasticity; Norway; Oral Sprays; Plant Extracts

2012
Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:3 Suppl 1

    Topics: Anti-Dyskinesia Agents; Cannabidiol; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Dronabinol; Drug Combinations; Drugs, Investigational; Humans; Multiple Sclerosis; Muscle Spasticity; Plant Extracts

2013
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Neurology, 2003, Feb-25, Volume: 60, Issue:4

    Topics: Administration, Oral; Affect; Appetite; Cannabidiol; Cannabinoids; Cannabis; Clinical Trials, Phase III as Topic; Double-Blind Method; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Neuralgia; Plant Extracts; Reflex, Abnormal; Safety; Sleep; Switzerland; Treatment Outcome; United Kingdom

2003
Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.
    Journal of neuroimmunology, 2003, Volume: 137, Issue:1-2

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Cannabinoids; Cannabis; Confidence Intervals; Cross-Over Studies; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Phytotherapy; Plant Extracts

2003
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.
    The Journal of clinical investigation, 2003, Volume: 111, Issue:8

    Topics: Animals; Benzoxazines; Brain; Cardiovirus Infections; Cytokines; Disease Models, Animal; Dronabinol; Female; Hypersensitivity, Delayed; Lymphocyte Activation; Mice; Morpholines; Multiple Sclerosis; Myelin Proteolipid Protein; Naphthalenes; Peptide Fragments; RNA, Messenger; Theilovirus; Viral Load

2003
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Lancet (London, England), 2003, Nov-08, Volume: 362, Issue:9395

    Topics: Administration, Oral; Cannabidiol; Cannabinoids; Double-Blind Method; Dronabinol; Drug and Narcotic Control; Humans; Multicenter Studies as Topic; Multiple Sclerosis; Muscle Spasticity; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; United States

2003
Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?
    The Journal of pharmacy and pharmacology, 2003, Volume: 55, Issue:12

    Topics: Animals; Anticonvulsants; Brain; Cannabis; Chromatography, High Pressure Liquid; Disease Models, Animal; Dronabinol; Epilepsy; Membrane Potentials; Mice; Multiple Sclerosis; Phytotherapy; Plant Preparations; Rats

2003
Marijuana as a treatment for epilepsy and multiple sclerosis? A "grass roots" movement.
    Neurology, 2004, Jun-08, Volume: 62, Issue:11

    Topics: Animals; Canada; Cannabis; Dronabinol; Drug and Narcotic Control; Drug Utilization; Epilepsy; Humans; Kindling, Neurologic; Multiple Sclerosis; Phytotherapy; Plant Preparations; Public Opinion; United States

2004
Medicinal cannabis extracts for the treatment of multiple sclerosis.
    Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:7

    Topics: Animals; Cannabis; Chronic Disease; Clinical Trials, Phase III as Topic; Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic

2004
GW-1000. GW Pharmaceuticals.
    Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:7

    Topics: Administration, Oral; Analgesics; Animals; Biological Availability; Canada; Cannabidiol; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dronabinol; Drug Approval; Drug Combinations; Drug Evaluation, Preclinical; Drug Industry; Humans; Hyperalgesia; Investigational New Drug Application; Mice; Molecular Structure; Multiple Sclerosis; Patents as Topic; Peripheral Nervous System Diseases; Phytotherapy; Plant Extracts; Plant Preparations; Randomized Controlled Trials as Topic; Spinal Cord Injuries; Structure-Activity Relationship

2004
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:4

    Topics: Adult; Cannabidiol; Cannabis; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Follow-Up Studies; Humans; Medical Records; Middle Aged; Multiple Sclerosis; Pilot Projects; Plant Extracts; Sensation; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder; Urinary Bladder, Neurogenic; Urinary Incontinence; Urination; Urodynamics

2004
Conditional okay for cannabis prescription drug.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, Jun-21, Volume: 172, Issue:13

    Topics: Canada; Cannabidiol; Cannabis; Dronabinol; Drug Approval; Drug Combinations; Humans; Multiple Sclerosis; Neuralgia; Phytotherapy; Plant Extracts

2005
Sativex for the management of multiple sclerosis symptoms.
    Issues in emerging health technologies, 2005, Issue:72

    Topics: Administration, Oral; Administration, Sublingual; Aerosols; Analgesics; Canada; Cannabidiol; Dronabinol; Drug Approval; Humans; Multiple Sclerosis; Muscle Spasticity; Pain; Phytotherapy; Plant Extracts; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Tremor; United Kingdom

2005
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
    Brain : a journal of neurology, 2007, Volume: 130, Issue:Pt 10

    Topics: Acute Disease; Adult; Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Corpus Striatum; Disease Models, Animal; Dronabinol; Electrophysiology; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Female; Glycerides; Humans; Lymphocytes; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Neuroprotective Agents; Patch-Clamp Techniques; Polyunsaturated Alkamides; Synaptic Transmission; Tissue Culture Techniques

2007
Cannabis; adverse effects from an oromucosal spray.
    British dental journal, 2007, Sep-22, Volume: 203, Issue:6

    Topics: Administration, Oral; Adult; Aerosols; Aged; Burns, Chemical; Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Drug Combinations; Female; Humans; Male; Middle Aged; Mouth Mucosa; Multiple Sclerosis; Pain; Phytotherapy; Plant Extracts

2007
Nabilone in the treatment of multiple sclerosis.
    Lancet (London, England), 1995, Mar-04, Volume: 345, Issue:8949

    Topics: Dronabinol; Humans; Male; Middle Aged; Multiple Sclerosis

1995
Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors.
    Lancet (London, England), 1999, Feb-13, Volume: 353, Issue:9152

    Topics: Analgesics; Dronabinol; Humans; Multiple Sclerosis; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Receptors, Opioid

1999
Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.
    Journal of neuroimmunology, 2000, Jan-03, Volume: 102, Issue:1

    Topics: Acute Disease; Animals; Brain; Dose-Response Relationship, Drug; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Injections, Intraperitoneal; Injections, Intravenous; Multiple Sclerosis; Neuroprotective Agents; Rats; Rats, Inbred Lew; Recurrence; Spinal Cord; Time Factors; Treatment Outcome

2000
Marijuana may lessen spasticity of MS.
    JAMA, 1979, Jun-08, Volume: 241, Issue:23

    Topics: Dronabinol; Humans; Multiple Sclerosis; Muscle Spasticity

1979